5-oxotetrahydro-2-furanyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-oxotetrahydro-2-furanyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
• 英文别名: (5-oxooxolan-2-yl) 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
• 化学式: C₂₉H₂₄N₄O₇
• 分子量: 540.532
• InChiKey: HOZIGBYDHWYHTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-hydroxybutanoic acid lactone 、 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以3.3%的产率得到5-oxotetrahydro-2-furanyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
  参考文献：
  名称：

  Benzimidazole derivative and use thereof

  摘要：

  本发明涉及一种化合物，其表示为式(I)，其中R1是由下式表示的基团，其中R2、R3、R4、R5、R6、R7和R8分别独立地是氢原子或C1-6烷基，或其盐。本发明的化合物可用作预防或治疗循环疾病（如高血压等）和代谢疾病（如糖尿病等）的药剂。

  公开号：

  US20050187269A1

文献信息

• Benzinidazole Derivative and Use As AII Receptor Antagonist
  申请人：Kuroita Takanobu

  公开号：US20060281795A1

  公开（公告）日：2006-12-14

  The present invention relates to a compound represented by the formula (I) wherein R 1 is a group represented by the formula wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently a hydrogen atom or a C 1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.

  本发明涉及一种由式(I)表示的化合物，其中R1是由式表示的基团其中R2、R3、R4、R5、R6、R7和R8各自独立地为氢原子或C1-6烷基或其盐。本发明的化合物可用作预防或治疗循环系统疾病，如高血压等，以及代谢性疾病，如糖尿病等的药物。
• Benzimidazole derivative and use as a II receptor antagonist
  申请人：Kuroita Takanobu

  公开号：US20090270464A1

  公开（公告）日：2009-10-29

  The present invention relates to a compound represented by the formula (I) wherein R 1 is a group represented by the formula wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently a hydrogen atom or a C 1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.

  本发明涉及一种化合物，其表示为公式（I），其中R1是由以下公式表示的基团： 其中R2、R3、R4、R5、R6、R7和R8各自独立地为氢原子或C1-6烷基，或其盐。本发明的化合物可用作预防或治疗循环系统疾病，如高血压等，以及代谢性疾病，如糖尿病等的药剂。
• Benzimidazole derivative and its use as aii receptor antagonist
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2119715A1

  公开（公告）日：2009-11-18

  The invention relates to a process for preparing a compound of formula (I): wherein R1 is a group represented by the formula: wherein R2, R3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or a C1-6 alkyl, or a salt thereof, which comprises reacting a compound of formula (II): or a salt thereof, with an acylating agent; with thionyl chloride or oxalyl chloride and then with an alcohol; with an alkylating agent; or with an alcohol.

  本发明涉及一种制备式 (I) 化合物的工艺： 其中 R1 是由式表示的基团： 其中 R2、R3、R4、R5、R6、R7 和 R8 各自独立地为氢原子或 C1-6 烷基、 或其盐，其中包括反应式 (II) 的化合物： 或其盐与酰化剂反应；与亚硫酰氯或草酰氯反应，然后与醇反应；与烷化剂反应；或与醇反应。
• Benzimidazole derivative and its use as AII receptor antagonist
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2119715B1

  公开（公告）日：2012-05-30
• BENZIMIDAZOLE DERIVATIVE AND ITS USE AS A II RECEPTOR ANTAGONIST
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1718641B1

  公开（公告）日：2007-08-15